Botanical formulations designed to support the Endocannabinoid System and promote general wellness and natural balance
EPI1 Immunotech develops research-guided botanical formulations designed to support the body's natural Endocannabinoid System and promote general wellness.
Our products are formulated with natural botanical compounds—including cannabinoids, palmitoylethanolamide (PEA), GABA, and curcuminoids—selected based on published research into wellness support.
We focus on three interconnected wellness areas: cognitive wellness, overall vitality, and immune wellness—providing botanical support for individuals seeking general well-being.
As the cost for healthcare in the US continues to rise, we believe the future of healthcare will depend not only on scientific excellence but on preventative, restorative care and equitable access — ensuring that the most advanced biotechnologies benefit everyone, not just the privileged few.
Our mission is to find effective, ethical, and affordable solutions that move beyond conventional pharmaceuticals while restoring balance to the body through data-driven science, regenerative innovation, and nutritional immunology.
To develop and provide research-guided botanical formulations that support the body's natural Endocannabinoid System, helping individuals promote general wellness, healthy stress response, and natural balance through safe and accessible botanical support.
We believe wellness begins with understanding and supporting the body's natural systems. Our mission is to bridge the gap between botanical research and practical application—making research-guided formulations accessible to those seeking natural support for general well-being.
Through rigorous quality standards, transparent formulation practices, and commitment to research, we aim to empower individuals on their wellness journey—providing botanical support that works with the body's natural systems.
The principles that guide everything we do
We pursue innovation not as novelty, but as necessity. By uniting AI-driven research, nutritional immunology, regenerative materials, and stem-cell technology, we transform today's limitations into tomorrow's standard of care.
Data is the lifeblood of discovery. We secure, organize, and learn from it through blockchain transparency and AI intelligence, turning information into action.
Breakthroughs demand precision. We deliver on our promises through disciplined planning, measurable performance, and accountability in every experiment, partnership, and patient interaction.
True innovation only matters when it reaches everyone. We design our therapies, technologies, and business models to be scalable, affordable, and inclusive.
Human safety is the foundation of all progress. From laboratory research to clinical care, we build safeguards into every process, protecting both the body and the data of every person who entrusts us with their health.
Building an end-to-end scientific ecosystem where discovery, production, clinical data, and treatment coexist
AI and blockchain technology to create unified data infrastructure that secures patient information and transforms data into actionable insights
A scalable, end-to-end scientific ecosystem that integrates research, manufacturing, and clinical care within a single connected framework
Research in regenerative, immunology, and nutritional science to develop safe, effective, and affordable alternatives to conventional drugs
A new model of healthcare that is more affordable, efficient, and transparent than current structures
What sets EPI1 apart in the biotechnology landscape
Artificial intelligence now defines the frontier of drug development, with the global AI-in-biotech sector expected to exceed $80 billion by 2032.
EPI1's proprietary AI engine is not a peripheral tool but the central nervous system of our operation — continuously analyzing data across research, manufacturing, and clinical performance to refine efficacy and accelerate discovery.
By transforming patient records into secure, blockchain-based digital assets, our system ensures privacy, transparency, and traceability across every stage of research and care. The integrated AI continuously analyzes this data to identify trends, optimize treatment protocols, and improve outcomes, creating a self-learning network that reduces inefficiency, eliminates fraud, and empowers both physicians and patients.
The demand for safe, affordable immune modulation is surging. EPI1's formulations target cytokine imbalance, oxidative stress, and systemic inflammation — the common threads linking post-viral illness, autoimmune disease, and chronic fatigue syndromes. This versatility allows EPI1 to enter multiple adjacent markets simultaneously, spanning both clinical and consumer channels.
Projected to surpass $30 billion by 2030, the stem cell market is one of the fastest-growing sectors in medicine.
EPI1's AI-assisted stem cell division integrates directly into our clinical workflow, providing autologous and allogeneic solutions for immune restoration and regenerative healing — bridging research innovation and real-world therapy within a single ecosystem.
With global wound-care markets exceeding $20 billion, EPI1's bioactive sutures use regenerative polymers to accelerate healing and modulate inflammation at the site of injury.
This technology expands the company's regenerative reach beyond molecular therapies into surgical and structural medicine.
Dallas and Houston facilities form the physical foundation of our end-to-end scientific ecosystem
Research & Manufacturing Hub
Clinical & Wellness Hub
Together, the Dallas and Houston campuses form a closed-loop research network connecting data, formulation, analysis, and clinical application.
Data from manufacturing in Dallas flow directly into Houston's patient-outcome records, while clinical results feed back into the AI-driven design process, enabling rapid iteration and continuous improvement. This system ensures traceability across every stage—from raw materials through molecular validation to patient response—while maintaining regulatory alignment and audit readiness.
By integrating laboratory, manufacturing, and clinical infrastructure, EPI1 can function autonomously while remaining connected through a secure AI data network. This modular design enables replication across geographies, allowing the company to scale globally while tailoring operations to local health needs.
Strategic roadmap for transforming healthcare delivery
EPI1 Immunotech envisions a world where research-guided botanical formulations support the body's natural wisdom—working with the Endocannabinoid System to help promote wellness and natural balance.
We're committed to developing quality formulations based on botanical research, providing individuals with safe, accessible, and research-guided options for supporting their general well-being.
Our vision: Make natural, research-guided wellness support accessible to everyone seeking to support their body's natural balance.
Whether you're a patient seeking innovative treatment, a researcher interested in collaboration, or an investor looking to support groundbreaking biotechnology — we want to hear from you.